Nasal polyposis and risk of the airway‘s inflammation development

E. Kologrivova, R. Pleshko, A. Starokha, P. Isaev (Tomsk, Russian Federation)

Source: Annual Congress 2008 - Risk factors for asthma versus asthma control
Session: Risk factors for asthma versus asthma control
Session type: Thematic Poster Session
Number: 3695
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. Kologrivova, R. Pleshko, A. Starokha, P. Isaev (Tomsk, Russian Federation). Nasal polyposis and risk of the airway‘s inflammation development. Eur Respir J 2008; 32: Suppl. 52, 3695

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Incidence of nasal polyposis and its association with the development of chronic bronchitis and/or emphysema
Source: Eur Respir J 2002; 20: Suppl. 38, 401s
Year: 2002

Treatment of nasal polyposis in aspirine sensitive asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 425s
Year: 2001

Pathophysiology of airway hyperresponsiveness in patients with nasal polyposis
Source: Annual Congress 2011 - Phenotyping airway diseases
Year: 2011


Nasal polyposis, analgesics intolerance and asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 428s
Year: 2001

Mepolizumab in the treatment of severe asthma with nasal polyposis: real-life study
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021


The clinical relationship of nasal polyposis to asthma and other pathologies in the French population
Source: Eur Respir J 2003; 22: Suppl. 45, 114s
Year: 2003

Nonallergic rhinitis, sinonasal polyposis and asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 108s
Year: 2003

Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020


Peculiarities of cytokine concentration in patients with nasal polyposis and asthmatic triad
Source: International Congress 2018 – Asthma, rhinitis and COPD: cells, mediators, biomarkers and genetics
Year: 2018

Nasal polyposis and asthma: the otorhinolaryngologist's view
Source: Eur Respir Monogr 2017; 76: 87-104
Year: 2017


Aspirin-induced urticaria/angioedema without respiratory symptoms in severe asthmatics with nasal polyposis
Source: Eur Respir J 2002; 20: Suppl. 38, 512s
Year: 2002

Dupilumab improves mental health measures in patients with chronic rhinosinusitis and nasal polyposis (CRSwNP)
Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases
Year: 2018




Treatment of inflammatory diseases of the nose
Source: ISSN=1025-448x, ISBN=1-904097-19-21, page=165
Year: 2001

Does ozone cause an inflammation on nasal mucosa?
Source: Eur Respir J 2006; 28: Suppl. 50, 671s
Year: 2006

Inflammatory and oxidative stress exhaled markers in nasal poliposis
Source: Eur Respir J 2004; 24: Suppl. 48, 679s
Year: 2004

Rhinitis, nasosinusal polyposis and asthma: clinical aspects
Source: ISSN=1025-448x, ISBN=1-904097-19-17, page=101
Year: 2001

Impact of biologic therapy in severe asthma with nasal polyps
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021


Impact of mepolizumab in severe asthma with nasal polyps
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021


Inflammatory endobronchial polyposis with bronchiectasis in cystic fibrosis
Source: Eur Respir J 2001; 18: 612-615
Year: 2001



Increased expression of IL-19 in metaplastic epithelium of patients with chronic rhinosinusitis and nasal polyps
Source: Annual Congress 2011 - Epithelial cell biology
Year: 2011